Specificity of α-cyano-β-hydroxy-β-methyl-N-[4- (trifluoromethoxy)phenyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 4264-4272

  Ghosh, Sutapa ^a   Zheng, Yaguo ^b   Jun, Xiao ^b   Mahajan, Sandeep ^b   Mao, Chen ^a   Sudbeck, Elise A ^a   Uckun, Fatih M ^b  

^a Parker Hughes Cancer Center   (United States)

^b PARKER HUGHES INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHOXY)PHENYL]CROTONAMIDE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CANCER SURVIVAL; CATALYSIS; CELL PROLIFERATION; DIMERIZATION; DRUG SPECIFICITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MEMBRANE BINDING; PRIORITY JOURNAL; PROTEIN DOMAIN;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; COS CELLS; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; NITRILES; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0033382016     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Carpenter, G., and Cohen, S. Epidermal growth factor. J. Biol. Chem., 265: 7709-7712, 1990.
2. George-Nascimento, C., Gyenes, A., Halloran, S. M., Merryweather, J., Valenzuela, P., Steimer, K. S., Masiarz, F. R., and Randolph, A. Characterization of recombinant human epidermal growth factor produced in yeast. Biochemistry, 27: 797-802, 1988.
3. Khazaie, K., Schirrmacher, V., and Lichtner, R. B. EGF receptor in neoplasia and metastasis (Review). Cancer Metastasis Rev., 12: 255-274, 1993.
4. Mendelsohn, J., and Baselga, J. Antibodies to growth factors and receptors. In: V. T. Devita, Jr., S. Helman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer: Principles and Practice, pp. 607-623. Philadelphia: J. B. Lippincott Co., 1995.
5. Yarden, Y., and Ullrich, A. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem., 57: 443-478, 1988.
6. Wright, J. D., Reuter, C. W., and Weber, M. J. An incomplete program of cellular tyrosine phosphorylations induced by kinase-defective epidermal growth factor receptors. J. Biol. Chem., 270: 12085-12093, 1995.
7. Earp, H. S., Dawson, T. L., Li, X., and Yu, H. Hetrodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat., 35: 115-132, 1995.
8. Toi, M., Osaki, A., Yamada, H., and Toge, T. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur. J. Cancer, 27: 977-980, 1991.
9. Chrysogelos, S. A., and Dickson, R. B. Mechanisms of EGF receptor regulation in breast cancer cells. Breast Cancer Res. Treat., 29: 29-40, 1994.
10. Fox, S. B., Smith, K., Hollyer, J., Greenall, M., Hastrich, D., and Harris, A. L. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat., 29: 41-49, 1994.
11. Moyer, J., Barbacci, E., Iwata, K., Arnold, L., Boman, B., Cunningham, A., DiOrio, C., Doty, J., Morin, M., Moyer, M., Neveu, M., Pollack, V., Pustilnik, L., Reynolds, M., Sloan, D., Theleman, A., and Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res., 57: 4838-4848, 1997.
12. Uckun, F. M., Narla, R. K., Jun, X., Zeren, T., Venkatachalam, T., Waddick, K., Rostostev, A., and Myers, D. E. Cytotoxic activity of EGF-genistein against human breast cancer cells. Clin. Cancer Res., 4: 901-912, 1998.
13. Fry, D. W., and Bridges, A. J. Inhibitors of protein tyrosine kinases. Curr. Opin. Biotechnol., 6: 662-667, 1995.
14. Wakeling, A. E., Barker, A. J., Davies, D. H., Brown, D. S., Green, L. R., Cartlidge, S. A., and Woodburn, J. R. Specific inhibitors of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res. Treat., 38: 67-73, 1996.
15. Ghosh, S., Zheng, Y., Jun, X., Narla, R., Mahajan, S., Navara, C., Mao, C., Sudbeck, E. A., and Uckun, F. M. α-Cyano-β-hydroxy-β-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the EGF receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. Clin. Cancer Res., 4: 2657-2668, 1998.
16. Narla, R. K., Liu, X. P., Myers, D. E., and Uckun, F. M. 4-(3′-Bromo-4′ hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154): a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin. Cancer Res., 4: 1405-1414: 1998.
17. Sicheri, F., Moarefi, I., and Kuriyan, J. Crystal structure of the Src family tyrosine kinase Hck. Nature (Lond.), 385: 602-609, 1997.
18. Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yen, B. K., Hubbard, S. R., and Schlessinger, J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science (Washington DC), 276: 955-960, 1997.
19. Hubbard, S. R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J., 16: 5572-5581, 1997.
20. Zheng, J., Trafny, E. A., Knighton, D. R., Xuong, N-H., Taylor, S. S., Ten Eyck, L. F., and Sowadski, J. M. 2.2Å refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr., D49: 362-365, 1993.
21. Sudbeck, E. A., Liu, X. P., Narla, R. K., Mahajan, S., Ghosh, S., Mao, C., and Uckun, F. M. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing anti-leukemic agents. Clin. Cancer Res., 5: 1569-1582, 1999.
22. Mahajan, S., Ghosh, S., Sudbeck, E. A., Zheng, Y., Downs, S., Hupke, M., and Uckun, F. M. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (btk): LFM-A13 [α-cyano-β-hydroxy-β-methyl-n-(2,5-dibromophenyl) propenamide]. J. Biol. Chem., 274: 9587-9599, 1999.
23. Rowley, R. B., Bolen, J. B., and Fargnoli, J. Molecular cloning of rodent p72Syk. Evidence of alternative mRNA splicing. J. Biol. Chem., 270: 12659-12664, 1995.
24. Bohm, H. J. LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J. Comput. Aided Mol. Des., 6: 593-606, 1992.
25. Bohm, H. J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput. Aided Mol. Des., 8: 243-256, 1994.
26. Vassilev, A., Ozer, Z., Navara, C., Mahajan, S., and Uckun, F. M. Bruton's tyrosine kinase (BTK) as an inhibitor of the Fas/CD95 death inducing signaling complex (DISC). J. Biol. Chem., 274: 1646-1656, 1999.
27. Goodman, P. A., Niehoff, L. B., and Uckun, F. M. Role of tyrosine kinases in induction of the c-jun proto-oncogene in irradiated B-lineage lymphoid cells. J. Biol. Chem., 273: 17742-17748, 1998.
28. Mahajan, S., Fargnoli, J., Burkhardt, A. L., Kut, S. A., Saouaf, S. J., and Bolen, J. B. Src family protein tyrosine kinases induce autoactivation of Bruton's tyrosine kinase. Mol. Cell. Biol., 15: 5304-5311, 1995.
29. Saouaf, S. J., Kut, S. A., Fargnoli, J., Rowley, R. B., Bolen, J. B., and Mahajan, S. Reconstitution of the B cell antigen receptor signaling components in COS cells. J. Biol. Chem., 270: 27072-27078, 1995.
30. Uckun, F. M., Waddick, K. G., Mahajan, S., Jun, X., Takata, M., Bolen, J., and Kurosaki, T. Bruton's tyrosine kinase as a mediator of radiation-induced apoptosis in B-lineage lymphoid cells. Science (Washington DC), 22: 1096-1100, 1996.
31. Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick, K. G., Ahlgren, L. T., Chelstrom, L. M., Burkhardt, A., Bolen, J., and Myers, D. E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science (Washington DC), 267: 886-891, 1995.
32. Bridges, A. J., Zhou, H., Cody, D. R., Rewcastle, G. W., McMichael, A., Showalter, H. D., Fry, D. W., Kraker, A. J., and Denny, W. A. Tyrosine kinase inhibitors: 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dime-thoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem., 39: 267-276, 1996.
33. Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., and Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor. Science (Washington DC), 265: 1093-1095, 1994.
34. Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., McNamara, D. J., Nelson, J. M., Sherwood, V., Smaill, J. B., Trumpp-Kallmeyer, S., and Dobrusin, E. M. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA, 95: 12022-12027, 1998.
35. Traxler, P., Bold, G., Frei, J., Lang, M., Lydon, N., Mett, H., Buchdunger, E., Meyer, T., Mueller, M., and Fure, t. P. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J. Med. Chem., 40: 3601-3616, 1997.
36. Xu, X., Williams, J. W., Gong, H., Finnegan, A., and Chong, A. S. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem. Pharmacol., 52: 527-534, 1996.
37. Mattar, T., Kochhar, K., Bartlett, R., Bremer, E. G., and Finnegan, A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett., 334: 161-164, 1993.
38. Bacon, D. J., and Anderson, W. F. A fast algorithm for rendering space-filling molecule pictures. J. Mol. Graphics, 6: 219-220, 1988.
39. Kraulis, P. MOLSCRIPT: a program to produce both detailed and schematic plots of proteins. J. Appl. Crystallogr, 24: 946-950, 1991.
40. Merritt, E. A., and Murphy, M. E. P. Raster3D Version 2.0-a program for photorealistic molecular graphics. Acta Crystallogr., D50: 869-873, 1994.